Active Lifestyles Key for Parkinson’s Advocates Zenner-Dolan, Kwok as They Await Advancements in Treatments
By Alexander Diegel
Author Archive: Roxan Olivas
C-Path Announces New Board Members Bonnie A. Allin and Louis Breton
Allin and Breton join C-Path Board of Directors to support strategic visionContinue reading
C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research
TUCSON, Ariz., March 28, 2024 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.Continue reading
C-Path Announces New Executive Directors for Duchenne Regulatory Science Consortium and T1D Consortium
Appointments of Seasoned Researchers Reinforce C-Path’s Leadership in Accelerating Innovative Therapy DevelopmentContinue reading
C-Path, ActiGraph, and University of Canberra Collaborate to Generate Evidence to Support Regulatory Qualification of Novel Digital Health Technology Measures in Chronic Heart Failure
Collaboration will generate evidence to contribute to FDA qualification of a patient-centered, accelerometer-based clinical outcome assessment in CHFContinue reading
C-Path Promotes Cécile Ollivier to Vice President of Global Affairs, Expanding Leadership in Drug Development
Ollivier to steer global strategic initiatives, reinforcing C-Path’s commitment to accelerating medical innovation and regulatory science.Continue reading
C-Path’s TRxA Announces its 2024 Global Request for Proposals from Academic Investigators Working to Advance Drug Development Projects
NEW FUNDING OPPORTUNITY!
TUCSON, Ariz, January 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. Continue reading
C-Path to Lead New Task Force Aimed at Accelerating Drug Development for Mitochondrial and Inherited Metabolic Diseases
TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.Continue reading